← All trials
NCT05084560
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Nov 1, 2021
- Primary completion
- Jul 1, 2022
- Completion date
- Jul 31, 2022
- First posted
- Oct 20, 2021
- Last posted
- Oct 20, 2021
- Enrollment
- 80
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- University of LiverpoolLead sponsor
- EisaiCollaborator
- CovanceCollaborator
- University of LiverpoolOverall official - principal investigator
- Royal Liverpool & Broadgreen University Hospitals NHS TrutsCollaborator
- Subiaco Associates LimitedCollaborator
- SylexisCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.